FIDSA

Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers

Retrieved on: 
Tuesday, April 9, 2024
AXL, Infection, Drug discovery, COVID-19, RNA-dependent RNA polymerase, FACP, FIDSA, RNA, Research, Publishing, AI, UC San Diego Health, Deep learning, GALILEO, Preprint, Orthornavirae, Therapy, Pandemic, BioRxiv, MAS, BRD4

LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.

Key Points: 
  • LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.
  • Using bioinformatics and deep learning, they also found MDL-001 to be a promising orally bioavailable broad-spectrum antiviral that blocks the RdRp Thumb-1 site.
  • In the second preprint, "ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery" , Model Medicines details their foundational GALILEO AI platform and its core ChemPrint deep learning model for molecular property prediction.
  • By employing adaptive molecular embeddings and rigorous model training and validation methods, ChemPrint substantially outperformed conventional AI approaches.

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Retrieved on: 
Monday, January 29, 2024
Mortality, Patient, Leukemia, LAMB, Therapy, MD, FCCP, Infection, Biotechnology, Survival, Fungal infection, COVID, FAAM, Aspergillosis, Division, Immunodeficiency, Conference, Bone marrow, UCLA, Transplant, B♭ (musical note), Doctor of Philosophy, Antimalarial medication, FIDSA, Harbor–UCLA Medical Center, Lung, AAAM, Diabetes, Pharmaceutical industry

In this highly lethal mouse model of mucormycosis, SCY-247 showed very promising in vivo efficacy.

Key Points: 
  • In this highly lethal mouse model of mucormycosis, SCY-247 showed very promising in vivo efficacy.
  • This is comparable to the 40% survival observed in the control group treated with 10 mg/kg of intravenous standard of care of liposomal amphotericin B (LAMB) (p = 0.008 vs. placebo).
  • The combination treatment of SCY-247 plus LAMB demonstrated the greatest reduction in fungal burden and was highly statistically significant in both lung and brain tissue (both p
  • “These positive data continue to accumulate and define the unique properties of SCY-247, highlighting its potential to be differentiated from currently available antifungals.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Monday, November 20, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Sale, Heart, Southampton General Hospital, Pediatrics, Patient, Conference, Doctor of Philosophy, Viral, Webcast, Safety, RSV, Human, Respiratory system, MBBS, Federal, Chronic obstructive pulmonary disease, Texas A&M University, O'Driscoll (surname), Dean (education), Respiratory Medicine, Pharmacokinetics, University, FRCP, Fast Track, Asthma, Medication, Infection, FERS, Urinary tract infection, Virology, Ageing, Upper respiratory tract infection, Viral load, Clinical trial, Tax, HBV, FDA, Vaccine, Faculty, OMERS, HCV, State Administrative Expenses, Pharmaceutical industry, Life insurance, Cryptocurrency, Pfizer, Cantab, FIDSA, FAAP, Medicine, MD

(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.

Key Points: 
  • (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.
  • For the twelve months ended September 30, 2023, total revenue was $79.2 million compared to $86.2 million for the same period in 2022.
  • The decrease in the quarter and in year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET®/MAVIRET®.
  • Non-cash interest expense was $3.2 million for the three months ended September 30, 2023 and $5.1 million for the twelve months ended September 30, 2023.

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline

Retrieved on: 
Friday, October 13, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Southampton General Hospital, FRCP, Senior, Dean (education), Doctor of Philosophy, MBBS, University of Southampton, National Alliance for Hispanic Health, Texas A&M University, Viral, Virology, The Global Institute for Tomorrow, University, FERS, Respiratory Medicine, Medical school, Webcast, Faculty, Medication, RSV, Pharmaceutical industry, Management, Pediatrics, MD, FAAP, Medicine, Cantab, FIDSA

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for RSV with global experts and highlight the company’s RSV pipeline.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for RSV with global experts and highlight the company’s RSV pipeline.
  • The event will feature presentations and discussions with:
    Jamie Fergie, MD, FAAP, FIDSA, FSHEA – Medical Director, Global Institute for Hispanic Health, Professor of Pediatrics, Texas A&M University and Director, Infectious Diseases, Driscoll Children’s Hospital
    Tom Wilkinson, MA (Cantab), MBBS, PhD, FRCP, FERS – Professor of Respiratory Medicine and Associate Dean, University of Southampton and Faculty of Medicine, Southampton General Hospital
    The event will be led by Jay R. Luly, PhD, President and Chief Executive Officer of Enanta, who will be joined by Scott T. Rottinghaus, MD, Senior Vice President and Chief Medical Officer, and John DeVincenzo, MD, Vice President of Translational Virology.
  • Event details are as follows:
    A webcast of the event will be available on the investor relations page of the Enanta Pharmaceuticals website at https://ir.enanta.com/events-presentations .
  • A replay of the webcast will be archived on Enanta’s website for at least 30 days following the presentation.

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Retrieved on: 
Wednesday, October 11, 2023
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Nursing care plan, FCCP, Philippe Ciais, Food, Doctor of Philosophy, Division, Multidrug-resistant bacteria, Development, MD, Synergy, Infection, Meropenem, Therapy, Sulbactam, Combination, Food and Drug Administration, Fungal infection, Cefepime, Pseudomonas aeruginosa, FIDSA, Doctor of Pharmacy, Hartford Hospital, Research, Pharmaceutical industry, Vaccine, Antibiotics, Imipenem, Enterobacterales

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today plans to present an oral abstract and four poster sessions from their portfolio of U.S. Food and Drug Administration (FDA)-approved critical care and infectious disease therapies at IDWeek 2023, October 11-15, held in Boston, MA.

Key Points: 
  • Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today plans to present an oral abstract and four poster sessions from their portfolio of U.S. Food and Drug Administration (FDA)-approved critical care and infectious disease therapies at IDWeek 2023, October 11-15, held in Boston, MA.
  • XACDURO is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
  • In addition, four company-sponsored research studies on XACDURO will also be presented by the company’s research partners in poster sessions.
  • “Antibiotic-resistant pathogens are one of the most significant and challenging threats to healthcare providers on the frontlines of infectious disease care,” said Margaret Koziel, MD, Chief Medical Officer, Innoviva Specialty Therapeutics.

RestorixHealth Welcomes Dr. William H. Tettelbach as New Chief Medical Officer

Retrieved on: 
Thursday, July 13, 2023
Research, Nursing, Surgery, Medical Supplies, Hospitals, Other Health, Managed Care, General Health, Health, Science, Newton, CWSP, Duke University, Medical Affairs Bureau, Intermountain Health, Monika Boehm-Tettelbach, Western University, FACP, Quality of life, Undersea and Hyperbaric Medical Society, Health informatics, MiMedx, Multimedia, Infection, CMO, 13th Waffen Mountain Division of the SS Handschar (1st Croatian), JWC, FIDSA, Medical director, MD, Patient, Outline of health sciences, Internal medicine, Mountain Division, HCA Healthcare, Hyperbaric medicine, Wound healing, Hospital, Podiatry

RestorixHealth, the nation’s leading wound care solutions company, has announced that Dr. William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP has been named Chief Medical Officer (CMO).

Key Points: 
  • RestorixHealth, the nation’s leading wound care solutions company, has announced that Dr. William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP has been named Chief Medical Officer (CMO).
  • He comes to RestorixHealth from HCA Healthcare, where he served as the Executive Medical Director, Wound & Hyperbaric Medicine Services for the Mountain Division.
  • View the full release here: https://www.businesswire.com/news/home/20230713335918/en/
    Dr. William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP has been named Chief Medical Officer (CMO) of RestorixHealth.
  • Dr. Tettelbach lends his expertise to numerous professional societies, committees and associations and has co-authored numerous research articles and book chapters.

BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

Retrieved on: 
Wednesday, May 10, 2023
Storm, Life, Atlas, Pathology, Phagocytosis, Massachusetts General Hospital, MBA, Harvard Medical School, Autoimmunity, Harvard University, Georgetown University, Eye, Wharton School of the University of Pennsylvania, Patient, Castleman Disease Collaborative Network, The New York Times, Faculty, Merck, Laboratory, Infection, BS, University, Research, EPA, Hematology, Hospital, Bacteria, FDA, Vaccine, NIH, Tufts University, Yale School of Medicine, Cancer, NLRP3, Biomarker, Hospital of the University of Pennsylvania, Public health, Publication, Saipan, Master of Science, Merck & Co., Therapy, Inflammation, Q&A, Autoinflammatory diseases, Penn, Internal medicine, Infectious Diseases Society of America, Immunosuppression, Gene, Flexner Report, GMA, Pharmaceutical industry, Nursing, MD, Brigham, FIDSA

The webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases will delve beneath the surface of this rapidly growing field of auto-inflammatory and hyper-inflammatory diseases.

Key Points: 
  • The webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases will delve beneath the surface of this rapidly growing field of auto-inflammatory and hyper-inflammatory diseases.
  • The major scientific breakthrough in identifying genes responsible for autoinflammatory diseases and related genotypes.
  • Key biomarkers for autoinflammatory diseases and new targets for treatments, like the NLRP3 inflammasome.
  • A live Q&A discussion with key opinion leader, David Fajgenbaum, MD, will follow the presentation.

UM SCHOOL OF MEDICINE RESEARCHERS CHART PATH FORWARD ON DEVELOPING MRNA VACCINES FOR INFECTIONS BEYOND COVID-19

Retrieved on: 
Friday, April 7, 2023
BioNTech, Injection, The New England Journal of Medicine, Medical Affairs Bureau, Pfizer, Human, University, Pediatric emergency medicine, Pediatrics, HIV, Vaccination, COVID-19, University of Maryland, College Park, Clinical trial, World Health Organization, Messenger, Plasmodium, Infection, CVD, Research, Cell, United Nations Foundation, Antibody, NEJM, Maryland School, PfSPZ Vaccine, Global Health, Death, Incidence, Influenza, Pandemic, United Nations, COVID-19 vaccine, Risk, University of Maryland School of Medicine, Disease, SE, Faculty, Mortality, Safety, Myron, RTS, Malaria, Vaccine, Science, Medicine, FIDSA, MD, MPH

BALTIMORE, April 7, 2023 /PRNewswire/ -- After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists are turning their attention to utilizing this innovative technology to ward off other infectious diseases like malaria and influenza. Last month, UMSOM faculty in the Center for Vaccine Development and Global Health (CVD) launched a new clinical trial to investigate the use of mRNA technologies to create a vaccine against malaria. CVD Director Kathleen M. Neuzil, MD, MPH, FIDSA also provided commentary in the nation's leading medical journal on the feasibility of using mRNA to develop a universal influenza vaccine that could eliminate the need for seasonal shots.

Key Points: 
  • The huge success of mRNA vaccines to combat COVID-19 has opened up a new era in vaccine development, offering the potential for faster, more efficient, and more effective vaccine production.
  • Dr. Neuzil pointed to more than 20 studies underway or in the planning stages to test novel influenza vaccines utilizing this technology.
  • She commented on a recent animal study published in Science, which tested an mRNA vaccine against all 20 known influenza virus subtypes.
  • CVD researchers also recently launched a new clinical trial investigating an mRNA-based vaccine for malaria.

TripleBlind Announces Collaboration with Two University of Texas Health-Related Institutions to Advance Public Health Cancer Prevention

Retrieved on: 
Wednesday, March 29, 2023
University of Texas Southwestern Medical Center, MLS, WHNP-BC, University, Moses Austin, Cancer prevention, University of Texas System, University of Texas Health Science Center at San Antonio, Principal investigator, Cancer Prevention and Research Institute of Texas, University of Texas at Austin, Division, DRS, Research, Privacy, Electronic health record, APRN, Doctor of Philosophy, Hepatitis C, Hospital, Patient, HIPAA, Internal medicine, Diagnosis, Research institute, Health, MPH, Death, HCC, Infection, Software, Pharmaceutical industry, Medical device, FIDSA, MD

KANSAS CITY, Mo., March 29, 2023 (GLOBE NEWSWIRE) -- TripleBlind , the leader in automated, real-time data de-identification, today announced an agreement with The University of Texas Southwestern Medical Center and The University of Texas Health Science Center at San Antonio.

Key Points: 
  • KANSAS CITY, Mo., March 29, 2023 (GLOBE NEWSWIRE) -- TripleBlind , the leader in automated, real-time data de-identification, today announced an agreement with The University of Texas Southwestern Medical Center and The University of Texas Health Science Center at San Antonio.
  • With the help of TripleBlind's technology, the agreement aims to empower researchers to study the impact collaborative research has on quality of patient care.
  • The Cancer Prevention and Research Institute of Texas (CPRIT) recently announced $90 million in new grant funding for programs to address the need for better cancer prevention across Texas, including public health screening and treatment for Hepatitis C and Hepatitis B vaccination in patients from low-income South Texas communities.
  • Hepatitis C, a condition that is increasing in younger populations, is a cause of hepatocellular carcinoma liver cancer (HCC), which is the third leading cause of death worldwide .

FDA Clears 'Selux NGP System' for Rapid Antibiotic Susceptibility Testing

Retrieved on: 
Thursday, January 19, 2023
Biomedical Advanced Research and Development Authority, Infection, NGP, Development, Office of Inspector General, U.S. Department of Health and Human Services, AMR, Administration, CLSI, Regulation of tobacco by the U.S. Food and Drug Administration, Doctor of Pharmacy, FDA, Oregon Health & Science University, Death, BARDA, Food, ASPR, Patient, Oregon Health Plan, Cancer, HHS, Oregon Health and Science University Center for Women's Health, AST, Vaccine, Pharmaceutical industry, FIDSA

The FDA clearance is for Selux Diagnostics' in vitro antimicrobial resistance test, which determines a bacteria's susceptibility to 14 specific antimicrobial agents on the Selux Gram-Positive Panel.

Key Points: 
  • The FDA clearance is for Selux Diagnostics' in vitro antimicrobial resistance test, which determines a bacteria's susceptibility to 14 specific antimicrobial agents on the Selux Gram-Positive Panel.
  • Selux's NGP Gram-Negative panel is currently under review by the FDA.
  • "This clearance represents a significant advance in infectious disease care and the fight to address antibiotic resistance.
  • Our groundbreaking Selux NGP System holds the potential to save lives and decrease overreliance on broad-spectrum antibiotics, a key factor contributing to the rise of superbugs.